Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Exxon Mobil reported for 6 months of 2023

7/28/23 XOM

Sanofi reported for 6 months of 2023

7/28/23 SNY

Chevron reported for 6 months of 2023

7/28/23 CVX

TGC-2 reported for 6 months of 2023 by RAS

7/28/23 TGKB

Tatneft will finalize the economic evaluation of drilling wells in Libya in 2023

7/28/23 TATN

TNS Energy reported for 6 months of 2023 by RAS

7/28/23 TNSE

UTair in first half of the year increased passenger transportation by 10%

7/28/23 UTAR

Ashinskiy Metallurgical Plant reported for 6 months of 2023 by RAS

7/28/23 AMEZ

Bashinformsvyaz reported for 6 months of 2023 by RAS

7/28/23 BISVP

TRK reported for 6 months of 2023 by RAS

7/28/23 TORS